Professional
Added to YB: 2024-02-14
Pitch date: 2024-02-13
ALT [bearish]
Altimmune, Inc.
+66.52%
current return
Author Info
Kerrisdale Capital is a research-oriented investment firm that shares investment ideas. Sign up for the newsletter.
Company Info
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Market Cap
$577.7M
Pitch Price
$8.81
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.93
P/E
-4.09
EV/Sales
9.3K
Sector
Biotechnology
Category
special_situation
[SHORT] Kerrisdale Capital: Altimmune, Inc. - $ALT
$ALT's pemvidutide weight loss drug faces skepticism:can't compete w/ $OZMP,$MNJ on blood sugar mgmt,high 42% discontinuation rate,crowded pipeline. CEO's past failures+$200M COVID vax raise cast doubt on partnering for P3 trial funding. Cash low.
Read full article (16 min)